PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
The conversation is about choosing a topical antiandrogen for hair loss, with options including RU58841, CB0301, Pyrolutamide, Alfatradiol, and Fluridil. Users discuss their preferences and reasons for selecting specific treatments.
A user experienced positive hair regrowth after 108 days of using 0.5 mg daily Dutasteride and Alpecin caffeine shampoo, without Minoxidil. The discussion included advice on dosage, potential side effects, and comparisons with Finasteride and Minoxidil.
JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.
A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.
A user experienced unexpected hormone test results after 7 months on 1mg daily finasteride, noting a decrease in estradiol despite expectations of an increase. Other users suggested that hormone responses can vary and that finasteride might still be effective if DHT levels are within range, while also mentioning factors like circadian rhythm and stress that could impact results.
A user's experience with treating their hair loss using finasteride, minoxidil, RU58841, dermarolling, and nizoral; specifically discussing dosage levels of the medications and effects on libido.
A 19-year-old plans to start Dutasteride 0.5mg three times a week to combat genetic alopecia and preserve hair density, with concerns about potential shedding before prom. Users suggest starting the treatment after prom to avoid shedding, and provide advice on where to purchase the medication.
A user with Androgenetic Alopecia is seeking advice on hair growth treatments while planning for pregnancy. Current routine includes LaserCap, Nizoral Shampoo, scalp massage, The Ordinary Multi Peptide Serum, vitamin D, prenatal vitamins, and SEEN shampoo.
The conversation discusses treatments for androgenetic alopecia, focusing on evidence-based supplements to complement finasteride. Suggestions include oral minoxidil, saw palmetto, pumpkin seed oil, tocotrienols, and various other supplements, while emphasizing the importance of scientific backing and cautioning against saw palmetto if already using finasteride.
A 31-year-old man with androgenic alopecia is considering treatments like finasteride, minoxidil, and ketoconazole shampoo but is worried about finasteride's side effects. Users recommend starting with finasteride or dutasteride for DHT blocking, suggesting topical solutions to reduce side effects.
Bimatoprost, latanoprost, and travoprost can aid hair regrowth but are costly and less effective than minoxidil. They work best when combined with minoxidil and finasteride.
PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.
A user is considering starting finasteride for hair loss and shares their hormone levels, with others suggesting checking SHBG and discussing potential side effects. Some recommend starting with 0.5 mg finasteride, while others suggest considering dutasteride.
The person is using 1mg of finasteride daily, 2mg of minoxidil, and weekly dermarolling with a 1mm needle. They sometimes use topical minoxidil as well.
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.
The conversation discusses using Morr F Aqua, an alcohol-free version of Minoxidil, for hair loss, particularly for someone with dandruff issues. The user is considering if this product is suitable for their condition.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.
A user is trying to reverse hair loss using vitamins E and D, jojoba oil, rosemary oil, peppermint oil, and microneedling, avoiding finasteride and minoxidil. They plan to use Alpecin shampoo and will provide updates on the effectiveness of this regimen.
The conversation discusses hair loss treatments, including dutasteride, oral minoxidil, finasteride, and potential additions like topical finasteride, minoxidil, micro-needling, and topical anti-androgens such as RU58841. The effectiveness and worth of these treatments, including localized dutasteride mesotherapy, are considered.
The conversation is about which blood tests are essential to check before starting hair loss treatment with finasteride or dutasteride. The tests mentioned include DHT, PSA, Estrogen/Estradiol, Testosterone, FSH, and LH.
The conversation is about personal experiences with Anagenic Pyrilutamid for hair loss and what carriers people use with it. No specific treatments or outcomes are mentioned.
The potential risks and benefits of using Dutasteride as a hair loss treatment, compared to using Finasteride or other treatments like RU58841 or Accutane. People discussed their personal experiences with these treatments and shared advice on how to proceed.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
A user shared their 1.5-year experience using 0.25mg finasteride daily for hair loss, noting significant hair quality improvements and reduced scalp itch but mild erectile dysfunction. They managed side effects with daily 2.5mg Cialis and 5mg citrulline and plan to continue this routine.